DK3395354T3 - Plasminogen til anvendelse i behandling af diabetisk nefropati - Google Patents

Plasminogen til anvendelse i behandling af diabetisk nefropati Download PDF

Info

Publication number
DK3395354T3
DK3395354T3 DK16874925.7T DK16874925T DK3395354T3 DK 3395354 T3 DK3395354 T3 DK 3395354T3 DK 16874925 T DK16874925 T DK 16874925T DK 3395354 T3 DK3395354 T3 DK 3395354T3
Authority
DK
Denmark
Prior art keywords
plasminogen
treatment
diabetic nephropathy
nephropathy
diabetic
Prior art date
Application number
DK16874925.7T
Other languages
English (en)
Inventor
Jinan Li
Original Assignee
Talengen Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Int Ltd filed Critical Talengen Int Ltd
Application granted granted Critical
Publication of DK3395354T3 publication Critical patent/DK3395354T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK16874925.7T 2015-12-18 2016-12-16 Plasminogen til anvendelse i behandling af diabetisk nefropati DK3395354T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015097944 2015-12-18
PCT/CN2016/110450 WO2017101868A1 (zh) 2015-12-18 2016-12-16 一种预防和治疗糖尿病肾病的方法

Publications (1)

Publication Number Publication Date
DK3395354T3 true DK3395354T3 (da) 2024-06-03

Family

ID=59055777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16874925.7T DK3395354T3 (da) 2015-12-18 2016-12-16 Plasminogen til anvendelse i behandling af diabetisk nefropati

Country Status (8)

Country Link
US (1) US11090372B2 (da)
EP (1) EP3395354B1 (da)
JP (1) JP6682008B2 (da)
CN (1) CN108778307A (da)
CA (1) CA3008686C (da)
DK (1) DK3395354T3 (da)
TW (1) TWI725092B (da)
WO (1) WO2017101868A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN108472342B (zh) 2015-12-18 2022-11-15 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
CN108463235A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种用于预防和治疗***的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP7194440B2 (ja) 2016-12-15 2022-12-22 タレンゲン インターナショナル リミテッド 心臓病変を改善するための方法
CN110114082A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
DK3556383T3 (da) 2016-12-15 2024-05-13 Talengen Int Ltd Plasminogen til anvendelse ved behandling af diabetes
WO2018233604A1 (zh) 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
JP7487970B2 (ja) * 2020-02-06 2024-05-21 タレンゲン インターナショナル リミテッド 多発性硬化症を予防及び治療する方法並びに薬剤
KR20220137946A (ko) * 2020-02-11 2022-10-12 탈렌젠 인터내셔널 리미티드 바이러스성 폐렴의 치료 방법 및 약물
WO2021170099A1 (zh) * 2020-02-26 2021-09-02 泰伦基国际有限公司 一种预防和治疗血压异常病症的方法和药物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1195375A (zh) 1995-04-26 1998-10-07 儿童医学中心公司 血管抑制素片段和集合血管抑制素及其使用方法
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
CA2344317C (en) 1998-09-29 2012-01-24 Leuven Research & Development Vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
WO2000044391A2 (en) 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
WO2001024815A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003210137A1 (en) 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
MX2007002177A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
JP2008539235A (ja) 2005-04-29 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007022321A2 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
ES2451015T3 (es) 2006-08-28 2014-03-26 Omnio Healer Ab Candidatos contra la infección
CA2703494A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of pai-1 production
KR101529743B1 (ko) 2007-11-29 2015-06-17 그리폴스 테라퓨틱스 인코포레이티드 재조합적으로 변형된 플라스민
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
EP2566514A4 (en) 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) * 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
EP2741767A1 (en) 2011-08-12 2014-06-18 ThromboGenics N.V. Plasminogen and plasmin variants
EP2914575B1 (en) 2012-10-31 2020-10-14 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
US9079739B2 (en) 2012-11-02 2015-07-14 The Procter & Gamble Company Apparatus for controlling the nip force/pressure between two rotating cylinders
ES2770507T3 (es) 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
BR112017012972A2 (pt) 2014-12-19 2018-02-27 Prometic Biotherapeutics Inc composição farmacêutica que compreende plasminogênio e seus usos
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CN108472342B (zh) 2015-12-18 2022-11-15 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
DK3556383T3 (da) 2016-12-15 2024-05-13 Talengen Int Ltd Plasminogen til anvendelse ved behandling af diabetes

Also Published As

Publication number Publication date
CN108778307A (zh) 2018-11-09
CA3008686A1 (en) 2017-06-22
EP3395354A1 (en) 2018-10-31
CA3008686C (en) 2023-03-14
JP6682008B2 (ja) 2020-04-15
TW201722466A (zh) 2017-07-01
TWI725092B (zh) 2021-04-21
EP3395354B1 (en) 2024-05-22
US20190015485A1 (en) 2019-01-17
WO2017101868A1 (zh) 2017-06-22
JP2019500424A (ja) 2019-01-10
EP3395354A4 (en) 2019-06-12
US11090372B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3590543T3 (da) Medicinsk forbinding
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3778595T3 (da) Pancreatitisbehandling
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3231444T3 (da) Ny behandling
DK3524255T3 (da) Sammensætning til behandling af acne
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK3373874T3 (da) Medicinsk forbinding
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte